Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Neurology"
DOI: 10.1002/ana.25737
Abstract: To assess real‐world effectiveness of initial treatment with newer compared to injectable disease‐modifying therapies (DMTs) on disease activity in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS). read more here.
Keywords: real world; effectiveness initial; world effectiveness; modifying therapies ... See more keywords
Trends in the use of disease‐modifying therapies among reproductive‐aged women with multiple sclerosis in the United States from 2010 to 2019
Sign Up to like & getrecommendations! Published in 2022 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5411
Abstract: Multiple sclerosis (MS) is a chronic disease of the central nervous system that disproportionately affects women, with typical onset during reproductive age. Several disease‐modifying therapies (DMTs) are FDA‐approved to slow disease progression, but are not… read more here.
Keywords: modifying therapies; 2010 2019; disease modifying; multiple sclerosis ... See more keywords
Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
Sign Up to like & getrecommendations! Published in 2017 at "PharmacoEconomics"
DOI: 10.1007/s40273-017-0577-2
Abstract: Introduction and objectiveMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. MS is considered incurable; however, disease treatment has advanced significantly over the past several decades with the introduction of disease-modifying… read more here.
Keywords: modifying therapies; cost; disease modifying; cost effectiveness ... See more keywords
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2020.1795127
Abstract: ABSTRACT Introduction Alzheimer’s disease (AD) is the main cause of dementia and represents a huge burden for patients, carers, and healthcare systems. Extensive efforts for over 20 years have failed to find effective disease-modifying drugs.… read more here.
Keywords: discontinued disease; alzheimer disease; modifying therapies; disease modifying ... See more keywords
The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2016.1258366
Abstract: Abstract Background: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. Aims: To compare… read more here.
Keywords: relapsing remitting; modifying therapies; cost; disease modifying ... See more keywords
Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2016.1194203
Abstract: ABSTRACT Introduction: Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer’s disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to… read more here.
Keywords: methodology; alzheimer disease; modifying therapies; disease modifying ... See more keywords
Disease-modifying therapies for tauopathies: agents in the pipeline
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2019.1606715
Abstract: ABSTRACT Introduction: Tauopathies are heterogeneous clinicopathological entities characterized by abnormal neuronal and/or glial inclusions of the microtubule-binding protein tau. Primary tauopathies considered to be diseases correspond to a major class of frontotemporal lobar degeneration (FTLD)… read more here.
Keywords: tau; modifying therapies; primary tauopathies; disease modifying ... See more keywords
Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-067516
Abstract: Objectives Disease-modifying therapies (DMTs) can slow disease progression in multiple sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) progression among newly diagnosed people with MS in relation to the first… read more here.
Keywords: disability; progression; newly diagnosed; modifying therapies ... See more keywords
Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review
Sign Up to like & getrecommendations! Published in 2022 at "BioMed Research International"
DOI: 10.1155/2022/2122056
Abstract: Background Sickle cell disease (SCD) is a hemoglobinopathy with increasing global prevalence resulting in pain episodes and multiorgan complications. Complications of SCD have been shown to adversely impact health-related quality of life (HRQOL) comprised of… read more here.
Keywords: adherence; disease; modifying therapies; hrqol ... See more keywords
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/17562864211039648
Abstract: Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in… read more here.
Keywords: sclerosis therapy; sclerosis; modifying therapies; disease modifying ... See more keywords
A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
Sign Up to like & getrecommendations! Published in 2023 at "F1000Research"
DOI: 10.12688/f1000research.130285.1
Abstract: Cardiac amyloidosis (CA), a significant condition resulting in infiltrative cardiomyopathy and heart failure with preserved ejection fraction (HFpEF), is caused by extracellular deposition of amyloid fibrils in the heart. Even though this has been known… read more here.
Keywords: cardiac amyloidosis; cardiac complications; modifying therapies; advances diagnosis ... See more keywords